The detection of EGFR, BRAF and MET mutations and the analysis of ALK, ROS1, RET, and NTRK translocations have already been incorporated into the diagnostic standards of NSCLC and inhibitors of these kinases are in routine clinical use around the world. This evidence concerns the gene EGFR and non-small cell lung carcinoma.